Cidara Therapeutics Inc (CDTX)

• $12.15

  $12.57

  $12.34
  

  1.58%

  Downside

  Day's Volatility :3.34%

  Upside

  1.79%

  
• $10.00

  $27.60

  $12.34
  

  18.96%

  Downside

  52 Weeks Volatility :63.77%

  Upside

  55.29%

  

Returns

What analysts predicted

Upside of 558.43%

• Vanguard Group Inc

  3.67%

• Renaissance Technologies Corp

  1.98%

• Alethea Capital Management, LLC

  1.78%

• 5AM Venture Management, LLC

  1.24%

• BlackRock Inc

  1.03%

• Geode Capital Management, LLC

  0.88%

cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.